La FDA aprueba la primera pastilla para tratar la enfermedad de Crohn de moderada a grave
VIERNES, 19 de mayo de 2023 (HealthDay News) — Los pacientes con enfermedad de Crohn cuentan ahora con una nueva opción de tratamiento, después de que la Administración de Alimentos y Medicamentos (FDA) de EE. UU. aprobara una pastilla llamada Rinvoq…
Learn MoreFDA Approves First Pill to Treat Moderate-to-Severe Crohn Disease
FRIDAY, May 19, 2023 (HealthDay News) — Patients with Crohn disease have a new treatment option, following U.S. Food and Drug Administration approval of Rinvoq (upadacitinib).Rinvoq is meant to treat adults with moderately to severely active Crohn di…
Learn MoreFDA Approves First Pill to Treat Moderate-to-Severe Crohn’s Disease
FRIDAY, May 19, 2023 (HealthDay News) — Patients with Crohn’s disease have a new treatment option, following U.S. Food and Drug Administration approval of a pill called Rinvoq (upadacitinib).Rinvoq is meant to treat adults with moderately to severely…
Learn MoreFDA Approves First Nonhormonal Drug to Ease Menopause Hot Flashes
MONDAY, May 15, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved the first nonhormonal medication aimed at easing menopause hot flashes.The new pill, called Veozah (fezolinetant), is a neurokinin 3 (NK3) receptor antag…
Learn MoreLa FDA aprueba el primer fármaco para aliviar la agitación vinculada con el Alzheimer
JUEVES, 11 de mayo de 2023 (HealthDay News) — Un medicamento para tratar la agitación en los pacientes con Alzheimer cuenta ahora con la aprobación de la Administración de Alimentos y Medicamentos (FDA) de EE. UU.El jueves, la FDA otorgó una autoriza…
Learn MoreFDA Approves First Drug Meant to Ease Alzheimer Disease-Linked Agitation
THURSDAY, May 11, 2023 (HealthDay News) — A medication to treat agitation in patients with Alzheimer disease now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval for Rexulti (brexpiprazole) oral tablets on Th…
Learn MoreFDA Approves First Drug Meant to Ease Alzheimer’s-Linked Agitation
THURSDAY, May 11, 2023 (HealthDay News) — A medication to treat agitation in Alzheimer’s patients now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval to Otsuka Pharmaceutical Company Ltd., and Lundbeck Inc. …
Learn MoreFDA Approves Lumryz for Narcolepsy
THURSDAY, May 4, 2023 (HealthDay News) — The U.S. Food & Drug Administration has approved Lumryz for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy. Lumryz is an extended-release formulation of sodium oxybate to…
Learn MoreUn fármaco experimental para el Alzheimer ralentiza el declive del pensamiento en un ensayo avanzado
MIÉRCOLES, 3 de mayo de 2023 (HealthDay News) — Otro medicamento experimental para la enfermedad de Alzheimer parece tan promisorio que Eli Lilly, la compañía farmacéutica, planifica solicitar a la Administración de Alimentos y Medicamentos (FDA) de …
Learn MoreFDA Approves First RSV Vaccine
WEDNESDAY, May 3, 2023 (HealthDay News) — The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 years and older. Arexvy is expected to help prevent lower respirat…
Learn More